Drugs / Daratumumab and Hyaluronidase-fihj
Daratumumab and Hyaluronidase-fihj
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04566328 Background | Feb 2021 → Dec 2027 expected | plasma cell myeloma | ECOG-ACRIN Cancer Research Group | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Daratumumab and Hyaluronidase-fihj | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04566328 ↗ |
| Modality | Monoclonal antibody | “Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.” NCT04566328 ↗ |
| Route | Subcutaneous | “daratumumab subcutaneously (SC)” NCT04566328 ↗ |